Close

Eli Lilly & Co. (LLY) Unit to Acquire Rabies Vaccine Portfolio from Boehringer Ingelheim

Go back to Eli Lilly & Co. (LLY) Unit to Acquire Rabies Vaccine Portfolio from Boehringer Ingelheim

Boehringer Ingelheim Vetmedica Inc. Enters Into an Agreement to Sell U.S. Feline, Canine and Rabies Vaccines Portfolio to Elanco Animal Health

October 5, 2016 7:00 AM EDT

ST. JOSEPH, Mo., Oct. 5, 2016 /PRNewswire/ -- Boehringer Ingelheim Vetmedica Inc. (BIVI) today announced an agreement with Elanco U.S., Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), to sell a portfolio of U.S. canine, feline and rabies vaccines, as well as a fully integrated manufacturing and R&D site, to Elanco. The sale price of $885 million includes the estimated cost of acquired inventory. The deal is conditioned on antitrust approval and closing of the Boehringer Ingelheim (BI) asset swap transaction with Sanofi that was signed in June... More